secwatch.observer — SEC 8-K summary
======================================

Issuer:     Keros Therapeutics, Inc. (KROS)
CIK:        0001664710
Form:       8-K
Filed at:   2025-04-10T23:59:59+00:00
Accession:  0001664710-25-000033
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 3.03, 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Keros Therapeutics adopts poison pill and launches strategic review including potential sale
--------------------------------------------------------------------------------

- Board formed Strategic Committee to evaluate strategic alternatives including sale or business combination.
- Adopted limited-duration rights plan (10% threshold, 15% for passive institutional) expiring April 9, 2026.
- Rights plan triggered by an individual investor that disclosed 11.2% ownership as of April 6, 2025.
- Dividend of one right per common share for stockholders of record on April 24, 2025.
- Goldman Sachs & Co. LLC engaged as financial advisor; Cooley LLP as legal counsel.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1664710/000166471025000033/0001664710-25-000033-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1664710/000166471025000033/kros-20250409.htm
  HTML page:      https://secwatch.observer/filing/0001664710-25-000033

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer